# ANI Pharmaceuticals (ANIP) — Earnings

ANIP · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/anip/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $2.21 |
| EPS estimate | $2.04 |
| EPS surprise | +8.20% |
| Revenue surprise | +2.27% |
| Revenue | $266.0M |
| Revenue estimate | $260.1M |
| Reported | Aug 7, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1023024/000102302426000069/anip-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/76ecbb69-db74-cd08-9487-2ea97f3c2de0.html) |

ANI Pharmaceuticals reported Q2 2026 results on August 7, 2026. Earnings per share came in at $2.21, ahead of the $2.04 estimate by 8.20%. Revenue was $266.0 million, about 2% above the $260.1 million consensus and the highest in the table. Compared with Q2 2025, EPS rose about 23% from $1.80 and revenue rose about 26% from $211.4 million.

The longer record shows strong growth. Annual EPS rose from $1.41 in 2022 to $4.72 in 2023, $5.20 in 2024 and $7.87 in 2025. Annual revenue grew from $316.4 million to $883.4 million over the same years. The first half of 2026 adds up to $4.26 per share, about 22% more than the same period a year earlier. The highest quarterly EPS in the table was $2.33 in Q4 2025, and the only loss was Q1 2022, at $0.12 per share. ANI beat EPS estimates in 17 of the last 20 quarters, including every quarter since Q3 2022.

ANI has reported third-quarter results between November 1 and November 9 in each of the past five years. That points to early November 2026 for the next report. It will show whether revenue keeps growing from the Q2 level.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 7, 2026 | $2.04 | $2.21 | 8.20% | $260.1M | $266.0M |
| Q1 2026 | May 8, 2026 | $1.30 | $2.05 | 57.84% | $207.6M | $237.5M |
| Q4 2025 | Feb 27, 2026 | $1.98 | $2.33 | 17.55% | $231.4M | $247.1M |
| Q3 2025 | Nov 7, 2025 | $1.77 | $2.04 | 15.25% | $212.8M | $227.8M |
| Q2 2025 | Aug 8, 2025 | $1.41 | $1.80 | 28.05% | $190.1M | $211.4M |
| Q1 2025 | May 9, 2025 | $1.38 | $1.70 | 22.97% | $180.6M | $197.1M |
| Q4 2024 | Feb 28, 2025 | $1.44 | $1.63 | 13.59% | $175.4M | $190.6M |
| Q3 2024 | Nov 8, 2024 | $1.09 | $1.34 | 23.39% | $144.4M | $148.3M |
| Q2 2024 | Aug 6, 2024 | $0.95 | $1.02 | 7.37% | $129.1M | $138.0M |
| Q1 2024 | May 10, 2024 | $1.00 | $1.21 | 21.49% | $126.0M | $137.4M |
| Q4 2023 | Feb 29, 2024 | $0.86 | $1.00 | 16.96% | $124.9M | $131.7M |
| Q3 2023 | Nov 8, 2023 | $0.84 | $1.27 | 50.60% | $111.9M | $131.8M |
| Q2 2023 | Aug 9, 2023 | $0.67 | $1.28 | 91.99% | $99.9M | $116.5M |
| Q1 2023 | May 8, 2023 | $0.35 | $1.17 | 232.39% | $83.5M | $106.8M |
| Q4 2022 | Mar 9, 2023 | $0.67 | $0.76 | 13.10% | $86.0M | $94.2M |
| Q3 2022 | Nov 9, 2022 | $0.55 | $0.64 | 15.84% | $78.4M | $83.8M |
| Q2 2022 | Aug 8, 2022 | $0.22 | $0.13 | -40.91% | $72.0M | $73.9M |
| Q1 2022 | May 10, 2022 | $0.09 | −$0.12 | -228.62% | $65.0M | $64.5M |
| Q4 2021 | Mar 15, 2022 | $0.74 | $0.54 | -27.03% | $56.3M | $60.9M |
| Q3 2021 | Nov 1, 2021 | $0.70 | $1.01 | 44.29% | $49.7M | $52.1M |

## Frequently Asked Questions

### When did ANI Pharmaceuticals (ANIP) last report earnings?

ANI Pharmaceuticals last reported on Aug 7, 2026, covering fiscal Q2 2026.

### Did ANIP beat earnings estimates?

Yes. ANI Pharmaceuticals reported EPS of $2.21 for Q2 2026 against a $2.04 estimate — a 8.20% beat.

### How much revenue did ANIP report last quarter?

ANI Pharmaceuticals reported $266.0M in revenue for Q2 2026, against a consensus estimate of $260.1M.

## Similar Stocks

- [ADMA](https://www.lighthorse.io/tickers/adma) — ADMA Biologics Inc - Common Stock
- [ANVS](https://www.lighthorse.io/tickers/anvs) — Annovis Bio, Inc. Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).